Scott Libby Robert, Kramer Jordan J, Tue Nguyen Hoang Minh, Feibus Allison, Thomas Raju, Silberstein Jonathan L
Department of Urology, Tulane University School of Medicine, New Orleans, LA; Southeast Louisiana Veterans Health Care Services, New Orleans, LA.
Department of Urology, Tulane University School of Medicine, New Orleans, LA.
Clin Genitourin Cancer. 2017 Dec;15(6):e995-e999. doi: 10.1016/j.clgc.2017.04.018. Epub 2017 Apr 26.
African American (AA) men are known to have more aggressive prostate cancer (PCa) compared with Caucasian American men. We sought to determine predictors of subsequent detection and risk stratification of PCa in a racially diverse group of men with atypical small acinar proliferation (ASAP) on initial prostate biopsy.
A retrospective analysis was conducted on data from men with ASAP on initial prostate biopsy who subsequently received confirmatory biopsies between September 2000 and July 2015. Biopsies with more than 3 years between initial and confirmatory biopsies were excluded. Race, age, body mass index, transrectal ultrasound volume, serum prostate-specific antigen (PSA), PSA velocity, PSA density, and elapsed time between biopsies were assessed for predictive value in subsequent PCa diagnosis after an initial finding of ASAP.
Of 106 men analyzed, 75 (71%) were AA and 31 (29%) were non-AA. Baseline variables revealed AA men had higher PSA levels, PSA velocity, and PSA density (all P < .05). PCa was diagnosed in subsequent biopsy in 42 (40%) patients without significant racial variation; 30 (40%) AA versus 12 (39%) non-AA. Of the 42 PCa patients, 25 (24%) met Epstein criteria for significant disease without racial variation; 18 (24%) AA versus 7 (23%) non-AA. Only 10 (9%) patients had any component of Gleason 4; 7 (9%) AA versus 3 (10%) non-AA. In multivariate analysis, increasing age, PSA level, and PSA density were significant predictors of PCa.
AA men diagnosed with ASAP on initial prostate biopsy do not have increased risk of PCa on confirmatory biopsy compared with non-AA men.
众所周知,与美国白人男性相比,非裔美国(AA)男性患前列腺癌(PCa)的侵袭性更强。我们试图确定在初次前列腺活检时存在非典型小腺泡增生(ASAP)的不同种族男性群体中,后续PCa检测的预测因素和风险分层。
对2000年9月至2015年7月期间初次前列腺活检发现ASAP且随后接受确诊活检的男性数据进行回顾性分析。排除初次活检与确诊活检间隔超过3年的病例。评估种族、年龄、体重指数、经直肠超声测量体积、血清前列腺特异性抗原(PSA)、PSA速率、PSA密度以及活检间隔时间对初次发现ASAP后后续PCa诊断的预测价值。
在分析的106名男性中,75名(71%)为AA男性,31名(29%)为非AA男性。基线变量显示,AA男性的PSA水平、PSA速率和PSA密度更高(均P <.05)。42名(40%)患者在后续活检中被诊断为PCa,无明显种族差异;30名(40%)AA男性和12名(39%)非AA男性。在42名PCa患者中,25名(24%)符合Epstein重大疾病标准,无种族差异;18名(24%)AA男性和7名(23%)非AA男性。只有10名(9%)患者有任何Gleason 4成分;7名(9%)AA男性和3名(10%)非AA男性。多因素分析显示,年龄增加、PSA水平和PSA密度是PCa的显著预测因素。
与非AA男性相比,初次前列腺活检诊断为ASAP的AA男性在确诊活检时PCa风险并未增加。